Eli Lilly Signs $2.75B Deal to Bring AI-Developed Drugs to the Global Market
Eli Lilly has signed a $2.75 billion deal with Insilico Medicine to commercialize AI-developed therapies globally.
Eli Lilly has signed a $2.75 billion deal with Insilico Medicine to commercialize AI-developed therapies globally.
Utah launches an AI pilot for prescription renewals, letting algorithms handle routine medication management without physicians, highlighting regulatory and safety challenges.
Bristol Myers Squibb and Microsoft have launched a collaboration to accelerate early detection of lung cancer using AI-powered radiology tools, with a focus on underserved communities.
AI-native biotech Proxima raised $80 million in an oversubscribed seed round to develop proximity-based therapeutics. The funding supports AI-driven discovery for previously “undruggable” targets across oncology and immunology.
NVIDIA and Eli Lilly are creating a $1 billion AI co-innovation lab to accelerate drug discovery. The lab will integrate AI, biomedical data, and robotics to transform medicine development.